Literature DB >> 16159024

Recent developments in cathepsin K inhibitor design.

Urszula Grabowskal1, Timothy J Chambers, Masahiro Shiroo.   

Abstract

Cathepsin K is abundantly and selectively expressed in osteoclasts where it plays a critical role in bone degradation. Cathepsin K inhibitors are the first antiresorptive agents that prevent bone loss while allowing bone formation to continue, thereby enhancing the quality and ultimately the strength of bone. The development of cathepsin K inhibitors requires appropriate cell-based assays and animal models. Advances in reversible cathepsin K inhibitor design from January 2004 are reviewed herein.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16159024

Source DB:  PubMed          Journal:  Curr Opin Drug Discov Devel        ISSN: 1367-6733


  10 in total

Review 1.  Amide Bond Bioisosteres: Strategies, Synthesis, and Successes.

Authors:  Shikha Kumari; Angelica V Carmona; Amit K Tiwari; Paul C Trippier
Journal:  J Med Chem       Date:  2020-08-04       Impact factor: 7.446

2.  Cysteine Protease Cathepsins in Atherosclerosis and Abdominal Aortic Aneurysm.

Authors:  Sara Sjöberg; Guo-Ping Shi
Journal:  Clin Rev Bone Miner Metab       Date:  2011-06-18

3.  Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis?

Authors:  Izabela Podgorski
Journal:  Future Med Chem       Date:  2009-04       Impact factor: 3.808

Review 4.  Cathepsin K inhibitors for osteoporosis and potential off-target effects.

Authors:  Dieter Brömme; Fabien Lecaille
Journal:  Expert Opin Investig Drugs       Date:  2009-05       Impact factor: 6.206

Review 5.  Molecular probes for selective detection of cysteine cathepsins.

Authors:  Kelton A Schleyer; Lina Cui
Journal:  Org Biomol Chem       Date:  2021-07-21       Impact factor: 3.890

Review 6.  Antiresorptive drugs beyond bisphosphonates and selective oestrogen receptor modulators for the management of postmenopausal osteoporosis.

Authors:  J Y Reginster; A Neuprez; C Beaudart; M P Lecart; N Sarlet; D Bernard; S Disteche; O Bruyere
Journal:  Drugs Aging       Date:  2014-06       Impact factor: 3.923

7.  Targeting cathepsin K diminishes prostate cancer establishment and growth in murine bone.

Authors:  Weiping Liang; Fuhao Wang; Qiuyan Chen; Jinlu Dai; June Escara-Wilke; Evan T Keller; Johann Zimmermann; Ni Hong; Yi Lu; Jian Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2019-06-06       Impact factor: 4.553

Review 8.  Cathepsin K: A Versatile Potential Biomarker and Therapeutic Target for Various Cancers.

Authors:  Die Qian; Lisha He; Qing Zhang; Wenqing Li; Dandan Tang; Chunjie Wu; Fei Yang; Ke Li; Hong Zhang
Journal:  Curr Oncol       Date:  2022-08-22       Impact factor: 3.109

9.  Cathepsin K null mice show reduced adiposity during the rapid accumulation of fat stores.

Authors:  Marcella Funicello; Michela Novelli; Maurizio Ragni; Teresa Vottari; Cesare Cocuzza; Joaquin Soriano-Lopez; Chiara Chiellini; Federico Boschi; Pasquina Marzola; Pellegrino Masiello; Paul Saftig; Ferruccio Santini; Rene St-Jacques; Sylvie Desmarais; Nicolas Morin; Joseph Mancini; M David Percival; Aldo Pinchera; Margherita Maffei
Journal:  PLoS One       Date:  2007-08-01       Impact factor: 3.240

Review 10.  Advances in the discovery of cathepsin K inhibitors on bone resorption.

Authors:  Jun Lu; Maolin Wang; Ziyue Wang; Zhongqi Fu; Aiping Lu; Ge Zhang
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.